YuanhuaninCAS# 83133-14-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 83133-14-6 | SDF | Download SDF |
PubChem ID | 179680 | Appearance | Powder |
Formula | C22H22O11 | M.Wt | 462.4 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2-(3,4-dihydroxyphenyl)-7-methoxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one | ||
SMILES | COC1=CC2=C(C(=C1)OC3C(C(C(C(O3)CO)O)O)O)C(=O)C=C(O2)C4=CC(=C(C=C4)O)O | ||
Standard InChIKey | ZXVSQQSRCKKYLS-MIUGBVLSSA-N | ||
Standard InChI | InChI=1S/C22H22O11/c1-30-10-5-15-18(13(26)7-14(31-15)9-2-3-11(24)12(25)4-9)16(6-10)32-22-21(29)20(28)19(27)17(8-23)33-22/h2-7,17,19-25,27-29H,8H2,1H3/t17-,19-,20+,21-,22-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Yuanhuanin Dilution Calculator
Yuanhuanin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1626 mL | 10.8131 mL | 21.6263 mL | 43.2526 mL | 54.0657 mL |
5 mM | 0.4325 mL | 2.1626 mL | 4.3253 mL | 8.6505 mL | 10.8131 mL |
10 mM | 0.2163 mL | 1.0813 mL | 2.1626 mL | 4.3253 mL | 5.4066 mL |
50 mM | 0.0433 mL | 0.2163 mL | 0.4325 mL | 0.8651 mL | 1.0813 mL |
100 mM | 0.0216 mL | 0.1081 mL | 0.2163 mL | 0.4325 mL | 0.5407 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Polygalasaponin E
Catalog No.:BCN8754
CAS No.:882664-72-4
- Leachianol F
Catalog No.:BCN8753
CAS No.:164123-50-6
- Pueroside A
Catalog No.:BCN8752
CAS No.:100692-52-2
- Momordicine V
Catalog No.:BCN8751
CAS No.:1012315-36-4
- Cassiaglycoside II
Catalog No.:BCN8750
CAS No.:2241081-56-9
- Atractylochromene
Catalog No.:BCN8749
CAS No.:203443-33-8
- Leachianol G
Catalog No.:BCN8748
CAS No.:164204-62-0
- Marginatoxin
Catalog No.:BCN8747
CAS No.:1422536-56-8
- Polygalasaponin XXXV
Catalog No.:BCN8746
CAS No.:184479-28-5
- Momordicine II
Catalog No.:BCN8745
CAS No.:91590-75-9
- Quercetin 3-Caffeylrobinobioside
Catalog No.:BCN8744
CAS No.:957110-26-8
- Tessaric acid
Catalog No.:BCN8743
CAS No.:58142-10-2
- Ampelopsin G
Catalog No.:BCN8757
CAS No.:151487-09-1
- Torosachrysone 8-O-beta-gentiobioside
Catalog No.:BCN8758
CAS No.:94356-13-5
- ent-16beta,17-dihydroxy-9(11)-kauren-19-oic acid
Catalog No.:BCN8759
CAS No.:55483-24-4
- Microgrewiapine A
Catalog No.:BCN8760
CAS No.:1420777-30-5
- Rhamnocitrin 3-glucoside
Catalog No.:BCN8761
CAS No.:41545-37-3
- (1,5E,11E)-tridecatriene-7,9-diyne-3,4-diacetate
Catalog No.:BCN8762
CAS No.:201012-14-8
- 3,7,23,24-tetrahydroxycucurbita-5,25-dien-19-al
Catalog No.:BCN8763
CAS No.:1446447-97-7
- Orientalide
Catalog No.:BCN8764
CAS No.:72704-05-3
- Rhamnocitrin 3-apiosyl-(1→2)-glucoside
Catalog No.:BCN8765
CAS No.:148031-68-9
- Daidzein-4'-glucoside
Catalog No.:BCN8766
CAS No.:58970-69-7
- Formononetin-8-C-beta-D-apiofuranosyl-(1->6)-O-beta-D-glucopyranoside
Catalog No.:BCN8767
CAS No.:1147858-78-3
- Pueroside B
Catalog No.:BCN8768
CAS No.:100692-54-4
Identification of potential anticancer phytochemicals against colorectal cancer by structure-based docking studies.[Pubmed:31971455]
J Recept Signal Transduct Res. 2020 Feb;40(1):67-76.
Colorectal cancer (CRC) is the third most common malignancy among both the genders globally. Therefore, searching of new therapeutic options is utmost priority. Molecular docking is a widely used tool in drug discovery to identify potential new therapeutic targets. Molecular docking plays a vital role in the visualization of ligand-protein interaction at an atomic level and enhancing our understanding of the ligand behavior thus aiding in the structure-based drug designing. Selected phytochemicals with potential anticancer activities were examined for their binding affinities to the selected VEGFR and EGFR receptors. The receptor protein 3D structures were obtained from Protein Data Bank, and the molecular docking was performed using UCSF Chimera software with its AutoDock Vina tool. Out of 18 compounds screened, Yuanhuanin, Theaflavin, and Genistein have shown highest binding energies. Findings of this study should be further evaluated for their potential use in CRC treatment, management, and prevention.